RxDoctor Payments Data

Rashmi Prakash, MD

Family Medicine · Sarasota, FLNPI 1699273771

Payments from drug & device makers

$978in general payments, 2019–2025

Across 36 payments — averaging $27.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$213
  • Pfizer$184
  • Janssen Scientific Affairs, LLC$137
  • Exact Sciences$84
  • Dexcom, Inc.$69
  • Lilly USA, LLC$65
  • plus $225 from 6 others

What the payments were for

  • Food & beverage$978100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$978 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$84,398
Medicare patients
211
Services billed
882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide24$29,568
EliquisApixaban13$20,709
TrulicityDulaglutide15$14,554
MyrbetriqMirabegron11$8,663
Rivastigmine13$3,776
SynthroidLevothyroxine Sodium32$2,229
Levothyroxine Sodium141$1,301
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen59$1,194
Estradiol32$1,131
Rosuvastatin Calcium84$1,044
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine20$762
Metoprolol Succinate34$728
Amlodipine Besylate116$629
Pantoprazole Sodium42$626
Atorvastatin Calcium54$623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$65$44,12239 claims
PfizerEliquis$184$20,70913 claims
Astellas Pharma US IncMyrbetriq$37$8,66311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →